2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 08:30, 18 December 2023
, 18 December 2023→Bioavailability of NMN
| Line 111: | Line 111: | ||
* Taking 800 mg NMN per day increase blood cell NAD+ levels by ~43% in mild hypertension patients display significantly lower blood cell NAD+ levels.{{pmid|37718359}} | * Taking 800 mg NMN per day increase blood cell NAD+ levels by ~43% in mild hypertension patients display significantly lower blood cell NAD+ levels.{{pmid|37718359}} | ||
* Taking 300 mg NMN per day increase serum NAD+ levels by ~38%.{{pmid|35821806}} | * Taking 300 mg NMN per day increase serum NAD+ levels by ~38%.{{pmid|35821806}} | ||
* Whole blood NAD+ 0.176±0.063 -> 1.07±0.16 (250mg NMN/day), 0.194±0.081 -> 0.53±0.12 (placebo) | |||
{| class="wikitable" | |||
|+ | |||
! | |||
! colspan="2" |NMN Group | |||
! colspan="2" |Placebo Group | |||
!NMN group | |||
|- | |||
! | |||
! colspan="2" |NAD+ concentrate | |||
! colspan="2" |NAD+ concentrate | |||
!NAMN | |||
|- | |||
! | |||
!Baseline | |||
!After | |||
!Baseline | |||
!After | |||
!After | |||
|- | |||
|Whole blood, 250 mg/day{{pmid|35927255}} | |||
|0.176±0.063 | |||
|1.07±0.16 | |||
|0.194±0.081 | |||
|0.53±0.12 | |||
|3.51±1.86 | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|} | |||
== Controversy about NMN as Direct Precursor == | == Controversy about NMN as Direct Precursor == | ||